Insight and Treatment Outcomes in Schizophrenia: Post-hoc Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR.

Objective: The objective of this post-hoc analysis was to evaluate the effect of lurasidone and quetiapine extended-release (XR) on insight and judgment and assess the longitudinal relationships between improvement in insight and cognitive performance, functional capacity, quality of well-being, and depressive symptoms in patients with schizophrenia. Design: Clinically unstable patients with schizophrenia (N=488) were randomized to once-daily, fixed-dose treatment with lurasidone 80mg, lurasidone 160mg, quetiapine XR 600mg, or placebo, followed by a long-term, double-blind, flexible-dose continuation study involving these agents. Results: Significantly greater improvement in insight and judgment (assessed by the Positive and Negative Syndrome Scale G12 item) for the lurasidone and quetiapine XR groups, compared to the placebo group, was observed at Week 6. Over a subsequent six-month continuation period, the flexible dose lurasidone group showed significantly greater improvement in insight from acute phase baseline compared to the flexible-dose quetiapine XR group (QXR-QXR) (p=0.032). Improvement in insight was significantly correlated with improvement in cognition (p=0.014), functional capacity (p=0.006, UPSA-B), quality of well-being (p=0.033, QWB), and depressive symptoms (p=0.05, Montgomery-Åsberg Depression Rating Scale [MADRS] score) across treatment groups and study periods. Conclusion: In this post-hoc analysis, flexibly dosed lurasidone 40 to 160mg/d was found to be associated with significantly greater improvement in insight compared to flexibly dosed quetiapine XR 200 to 800mg/d over long-term treatment in patients with schizophrenia. Across treatment groups, improvement in insight and judgment was significantly associated with improvement in cognition, functional capacity, quality of well-being, and depressive symptoms over time.

[1]  A. Loebel,et al.  Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia , 2017, Schizophrenia bulletin.

[2]  R. Keefe,et al.  Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia , 2017, Schizophrenia Research.

[3]  A. Moustafa,et al.  Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients , 2016, International clinical psychopharmacology.

[4]  Michael F. Green,et al.  Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms. , 2015, Schizophrenia bulletin.

[5]  Philip D. Harvey,et al.  Effect of lurasidone dose on cognition in patients with schizophrenia: Post-hoc analysis of a long-term, double-blind continuation study , 2015, Schizophrenia Research.

[6]  Philip D. Harvey,et al.  Insight and subjective measures of quality of life in chronic schizophrenia , 2015, Schizophrenia Research: Cognition.

[7]  Philip D. Harvey,et al.  Self-assessment in schizophrenia: Accuracy of evaluation of cognition and everyday functioning. , 2015, Neuropsychology.

[8]  Philip D. Harvey,et al.  Factors influencing self-assessment of cognition and functioning in schizophrenia: Implications for treatment studies , 2015, European Neuropsychopharmacology.

[9]  R. Bentall,et al.  Subjective Cognitive Complaints in Schizophrenia: Relation to Antipsychotic Medication Dose, Actual Cognitive Performance, Insight and Symptoms , 2013, PloS one.

[10]  Philip D. Harvey,et al.  Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension , 2013, European Neuropsychopharmacology.

[11]  J. Kane,et al.  Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study , 2013, Schizophrenia Research.

[12]  S. Potkin,et al.  Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial , 2013, Schizophrenia Research.

[13]  A. Aleman,et al.  Changes in insight during treatment for psychotic disorders: A meta-analysis , 2013, Schizophrenia Research.

[14]  J. Kossowsky,et al.  The role of subjective illness beliefs and attitude toward recovery within the relationship of insight and depressive symptoms among people with schizophrenia spectrum disorders. , 2012, Journal of clinical psychology.

[15]  M. Kurtz,et al.  Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. , 2012, Schizophrenia bulletin.

[16]  Philip D. Harvey,et al.  Assessing everyday functioning in schizophrenia: Not all informants seem equally informative , 2011, Schizophrenia Research.

[17]  M. Kurtz,et al.  Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: What is their relationship? , 2011, Schizophrenia Research.

[18]  P. Snyder,et al.  A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia , 2009, Journal of clinical and experimental neuropsychology.

[19]  Philip D. Harvey,et al.  Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden. , 2009, The American journal of psychiatry.

[20]  G. Dimaggio,et al.  Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches , 2009, Expert review of neurotherapeutics.

[21]  J. Lieberman,et al.  Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. , 2009, Schizophrenia bulletin.

[22]  T. Patterson,et al.  Insight, quality of life, and functional capacity in middle‐aged and older adults with schizophrenia , 2008, International journal of geriatric psychiatry.

[23]  W. Rief,et al.  Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. , 2006, Schizophrenia bulletin.

[24]  B. Mausbach,et al.  Development of a brief scale of everyday functioning in persons with serious mental illness. , 2006, Schizophrenia bulletin.

[25]  J. Lieberman,et al.  Insight in first-episode psychosis , 2006, Psychological Medicine.

[26]  M. Olfson,et al.  Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia. , 2006, Psychiatric services.

[27]  G. Molenberghs.  Applied Longitudinal Analysis , 2005 .

[28]  Matcheri S. Keshavan,et al.  Correlates of insight in first episode psychosis , 2004, Schizophrenia Research.

[29]  R. Schwartz,et al.  Insight and illness in chronic schizophrenia. , 1998, Comprehensive psychiatry.

[30]  A. David,et al.  A comparative study of insight scales and their relationship to psychopathological and clinical variables , 1998, Psychological Medicine.

[31]  Robert M. Kaplan,et al.  The quality of well-being scale: Comparison of the interviewer-administered version with a self-administered questionnaire , 1997 .

[32]  R. Owen,et al.  Awareness of Illness in Schizophrenia and Outpatient Treatment Adherence , 1996, The Journal of nervous and mental disease.

[33]  M. Bell,et al.  Insight and Cognitive Impairment in Schizophrenia Performance on Repeated Administrations of the Wisconsin Card Sorting Test , 1994, The Journal of nervous and mental disease.

[34]  N C Andreasen,et al.  Awareness of illness in schizophrenia and schizoaffective and mood disorders. , 1994, Archives of general psychiatry.

[35]  G. Berríos,et al.  The assessment of insight in clinical psychiatry: a new scale , 1992, Acta psychiatrica Scandinavica.

[36]  A. David,et al.  Insight and Psychosis , 1990, British Journal of Psychiatry.

[37]  J. McEvoy,et al.  Insight in Schizophrenia. Its Relationship to Acute Psychopathology , 1989, The Journal of nervous and mental disease.

[38]  W. Wilson,et al.  Flexible system criteria in chronic schizophrenia. , 1986, Comprehensive psychiatry.

[39]  J. Castro-Fornieles,et al.  Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: a 2-year longitudinal study. , 2011, Schizophrenia bulletin.

[40]  X. Amador,et al.  Lessons learned about poor insight. , 2011, Schizophrenia bulletin.

[41]  X. Amador,et al.  Poor insight in schizophrenia , 2005, Psychiatric Quarterly.

[42]  J M Gorman,et al.  Awareness of illness in schizophrenia. , 1991, Schizophrenia bulletin.